Giannoula Karagouga
Overview
Explore the profile of Giannoula Karagouga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parikh K, Harris F, Karagouga G, Schrandt A, Mandrekar J, Johnson S, et al.
JTO Clin Res Rep
. 2024 Dec;
5(12):100692.
PMID: 39735890
Introduction: The spatially complex nature of mesothelioma and interventions like pleurodesis, surgery, and radiation often complicate imaging-based assessment. Further, cell-free DNA (cfDNA) based monitoring strategies are inadequate for mesothelioma, given...
2.
Gagnon M, Penheiter A, Harris F, Sadeghian D, Johnson S, Karagouga G, et al.
Blood Cancer J
. 2023 Dec;
13(1):190.
PMID: 38114462
No abstract available.
3.
Desai A, Kosari F, Disselhorst M, Yin J, Agahi A, Peikert T, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37279993
Background: Immune checkpoint inhibitors (ICIs) are now a first-line treatment option for patients with pleural mesothelioma with the recent approval of ipilimumab and nivolumab. Mesothelioma has a low tumor mutation...
4.
El Khoury L, Lin W, Smadbeck J, Barrett M, Sadeghian D, McCune A, et al.
Epigenomics
. 2023 May;
15(5):283-292.
PMID: 37212177
This work examines differences in chromatin accessibility, methylation, and response to DNA hypomethylating agents between mismatch repair-deficient and non-mismatch repair-deficient endometrial cancer. Next-generation sequencing of a stage 1B, grade 2...
5.
Gupta S, Nichols P, Lohse C, Kosari F, Kattah A, Harris F, et al.
Mayo Clin Proc
. 2022 Jun;
97(11):2050-2064.
PMID: 35753824
Objective: To profile juxtaglomerular cell tumors (JXG) and histologic mimics by analyzing renin expression; to identify non-JXG renin-producing tumors in The Cancer Genome Atlas (TCGA) data sets; and to define...
6.
Kosari F, Disselhorst M, Yin J, Peikert T, Udell J, Johnson S, et al.
J Thorac Oncol
. 2021 Nov;
17(3):446-454.
PMID: 34800701
Introduction: The favorable outcomes with immunotherapy for mesothelioma were somewhat unexpected because this tumor has a low tumor mutation burden which has been associated with benefit in other cancers. Because...
7.
Grassi T, Harris F, Smadbeck J, Murphy S, Block M, Multinu F, et al.
PLoS One
. 2021 Jun;
16(6):e0252390.
PMID: 34111149
Introduction: There are no reliable blood biomarkers for monitoring endometrial cancer patients in the current clinical practice. Circulating tumor DNA (ctDNA) is emerging as a promising non-invasive method to measure...
8.
Gleeson F, Jeraldo P, Levy M, Murphy S, Mendes-Soares H, Karagouga G, et al.
Gut
. 2021 Mar;
71(2):441-443.
PMID: 33753418
No abstract available.
9.
Murphy S, Levy M, Smadbeck J, Karagouga G, McCune A, Harris F, et al.
J Cell Mol Med
. 2021 Mar;
25(8):4110-4123.
PMID: 33704908
A crucial mutational mechanism in malignancy is structural variation, in which chromosomal rearrangements alter gene functions that drive cancer progression. Herein, the presence and pattern of structural variations were investigated...
10.
Murphy S, Smadbeck J, Eckloff B, Lee Y, Johnson S, Karagouga G, et al.
J Mol Diagn
. 2021 Jan;
23(4):375-388.
PMID: 33387698
DNA junctions (DNAJs) frequently impact clinically relevant genes in tumors and are important for diagnostic and therapeutic purposes. Although routinely screened through fluorescence in situ hybridization assays, such testing only...